Introduction
alterations associated with CDI. No single microbiota component has yet been linked to C. difficile 78 susceptibility; many different dysbiotic populations exist, all of which may predispose to CDI. 79 Work in rodents and in vitro gut models indicated that clindamycin exposure resulted in decreased 80 obligate anaerobic populations and a microbiota dominated by Enterobacteriaceae; [15] [16] [17] 81 cephalosporin exposure in Pseudomonadacae-and Lactobacillacaeae-dominated microbiota, 15, 19, 20 82 and tigecycline exposure in decreased in Bacteroidetes and increased Proteobacteria populations. 21, 83 22 These changes have been linked with CDI susceptibility to varying degrees and can persist longer 84 term; with microbiota populations taking up to a year to recover post-ciprofloxacin or clindamycin 85 treatment. 23 
86
There is considerable inter-individual variability of human microbiota profiles and discrepancies 87 between different clinical studies are evident. 14, 24 Defining microbiota changes associated with CDI 88 susceptibility is difficult, due to the range of antibiotic exposures and patient co-morbidities. In 89 general, CDI patients are reported to have decreased Bacteroides, Prevotella, Lachnospiraceae and 90
Bifidobacteria spp, and increased Lactobacilli, Ruminococci, Enterococci and Enterobacteriaceae 91 populations [24] [25] [26] 92 Studies suggest that decreased bacterial diversity is a common trait of all diarrhoeal samples, not 93 only those of CDI patients. 24, 25, 27 However, loss of bacterial diversity has been correlated with rCDI 94 clinically. 27 
100
The major paradox of CDI treatment is that while antibiotic therapy is a major risk factor for CDI, it is 101 also the first-line therapeutic option. 33 Thus, while CDI treatment may successfully inhibit vegetative 102 C. difficile populations, further disruption of the microbiota subsequent also occurs, increasing the 103 risk of CDI and contributing to the rCDI cycle (Figure 1) . Current guidelines recommend different 104 strategies for the treatment of initial CDI versus rCDI and can be found in more detail in Debast et 105 al. 7 However, a discussion of this topic is beyond the scope of this article. 106
Oral metronidazole and vancomycin were the primary CDI treatment options until recently. Both 107 agents have been linked to further gut microbiota disruption. Vancomycin extended the disruptionprimarily caused by clindamycin in both hamster s 33 (Bacteroidales , Clostridiales) and in vitro gut 109 models (Bacteroides fragilis group spp, bifidobacteria, clostridia). Gut concentrations of 110 metronidazole are low to undetectable (<0.25-9.5 mg/L), 34 and this was reflected in minor 111 microbiota disruption and poor efficacy against simulated CDI an in vitro gut model. 35 The high 112 recurrence rates associated with both these agents has led to development of narrower spectrum 113 antibiotics, with potent anti-C. difficile activity, but largely sparing of the gut microbiota. 55 This was attributed to a lower rate of rCDI with 139 ridinilazole (14%) compared with the vancomycin-treated group (35%).
Microbiota therapeutics 141
Tthere has been an increasing trend towards the use of microbiota therapeutics to restore the host 142 microflora. Initially, this focussed on faecal microbiota transplantation ( 57 An overall cure rate of 94% was reported, with a primary cure rate of 81% (13/16 subjects) 152
for FMT vs 23% (3/13) and 31% (4/13) cure rates for vancomycin and bowel lavage and vancomycin 153 alone respectively (10 week follow-up). A systematic review of 25 studies reported similar overall 154 success rates, with complete symptomatic resolution in 91% of patients (mean follow-up of 12.6 155 months), including 289 with refractory CDI treated by FMT.
58 Cure rates were unaffected by the 156 route of administration 59 or use of fresh or frozen faeces. SER-109 failed to achieve the primary efficacy endpoint of reduced CDI occurrence after 8 weeks. Distinguishing between relapse and reinfection is challenging, particularly as PCR ribotyping may lack 209 the power to discriminate between genotypically similar isolates. The picture is further complicated 210 by patients harbouring multiple C. difficile genotypes.
71 Some studies using more discriminatory 211 techniques suggest reinfection accounted for ~50% of recurrent infections, 72, ,73, 74, 77 86 However, it is also imperative to consider this against the underlying population 228 demographic as regional differences in prescribing and initial infection characteristics may influence 229 rCDI. 230
Persistence of C. difficile spores in the host gut
In recrudescent disease, spores must remain in the host gut and proliferate in response to agreeable 232 conditions. C. difficile vegetative cells can adhere to Caco-2, HeLa and HT-29 cells and extracellular 233 proteins in vitro, 87, 88 and two potential proteins responsible for this interaction have been 234
identified.
89 However, interaction with human colonic epithelia does not trigger germination. 
281

Conclusion 282
Whilst our understanding of the risk factors for rCDI has increased, it remains a continuing challenge. 283 Recurrent CDI is multifactorial, but two microbiological factors -the intestinal microbiota and C. 284 difficile spore germination -are key. The microbiota has become a major focus for breaking the rCDI 285 cycle, with novel narrow spectrum atimicrobials, FMT and next generation precision microbiota 286 therapies showing great treatment potential. However, further research is needed into the long 287 term implications of microbiota manipulation. The effects of treatment agents on spore production 288 and germination; retention within the host and environmental disessmination are comparatively 289 poorly understood, but crucial aspects of recurrent disease. 290 
